ArticleClinical and experimental immunology2019
Blood immune cell biomarkers in lung cancer.
Article in Clinical and experimental immunology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 41 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
41 citing papers in PubMed, 2 syntheses or guidelines pooled it, 55 citations in OpenAlex.
- Prognostic value of tumour-associated regulatory T-cells as a biomarker in non-small cell lung cancer: a systematic review and meta-analysis.Systematic reviews · 2024Pooled it
- The prognostic effects of circulating myeloid-derived suppressor cells in non-small cell lung cancer: systematic review and meta-analysis.Clinical and experimental medicine · 2023Pooled it
- Translational immune correlates of indirect antibody immunization in a randomized phase II study using scheduled combination therapy with carboplatin/paclitaxel plus oregovomab in ovarian cancer patients.Cancer immunology, immunotherapy : CII · 2020Trial
- Dynamics of blood neutrophil-related indices during nivolumab treatment may be associated with response to salvage chemotherapy for non-small cell lung cancer: A hypothesis-generating study.Thoracic cancer · 2019Trial
- Spatial imaging features derived from SUVmax location in resectable NSCLC are associated with tumor aggressiveness.European journal of nuclear medicine and molecular imaging · 2026Article
- Article
- The Importance of Predictive Biomarkers and Their Correlation with the Response to Immunotherapy in Solid Tumors-Impact on Clinical Practice.Biomedicines · 2024Review
- Synergistic B and T lymphocyte interaction: prognostic implications in non-small cell lung cancer.American journal of cancer research · 2024Article
- Causal association between immune cells and lung cancer risk: a two-sample bidirectional Mendelian randomization analysis.Frontiers in immunology · 2024Article
- Article
- Amino acid metabolism in immune cells: essential regulators of the effector functions, and promising opportunities to enhance cancer immunotherapy.Journal of hematology & oncology · 2023Review
- The Effect of Lung Resection for NSCLC on Circulating Immune Cells: A Pilot Study.Current oncology (Toronto, Ont.) · 2023Article
- Immunoprofiling bronchoalveolar lavage cells reveals multifaceted smoking-associated immune dysfunction.ERJ open research · 2023Article
- Monitoring Blood Immune Cells in Patients with Advanced Small Cell Lung Cancer Undergoing a Combined Immune Checkpoint Inhibitor/Chemotherapy.Biomolecules · 2023Observational
- A tri-specific killer engager against mesothelin targets NK cells towards lung cancer.Frontiers in immunology · 2023Article
- The influence of anti-cancer therapies on lymphocyte subpopulations of lung cancer patients.Frontiers in immunology · 2023Article
- Methods for assessment of the tumour microenvironment and immune interactions in non-small cell lung cancer. A narrative review.Frontiers in oncology · 2023Review
- Novel blood-based FUT7 DNA methylation is associated with lung cancer: especially for lung squamous cell carcinoma.Clinical epigenetics · 2022Article
- Identification of molecular subtypes in lung adenocarcinoma based on DNA methylation and gene expression profiling-a bioinformatic analysis.Annals of translational medicine · 2022Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Characterization of host immune cell parameters prior to treatment is expected to identify biomarkers predictive of clinical outcome as well as to elucidate why some patients fail to respond to immunotherapy. We monitored blood immune cells from 58 patients with non-small- cell lung cancer (NSCLC) undergoing surgery of the primary tumor and from 50 age-matched healthy volunteers. Complete leukocyte blood count, the number of circulating dendritic cells (DC), HLA-DR
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.